---
title: 'INSPIRED Symposium Part 5: Expanding the Use of CAR T cells in Children and
  Young Adults'
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38588880/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240409180657&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable
  efficacy in relapsed/refractory (r/r) B cell malignancies, including in pediatric
  patients with acute lymphoblastic leukemia (ALL). Expanding this success to other
  hematologic and solid malignancies is an area of active research and, although challenges
  remain, novel solutions have led to significant progress over the past decade. Ongoing
  clinical trials for CAR T cell therapy for T cell malignancies and acute ...
disable_comments: true
---
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute lymphoblastic leukemia (ALL). Expanding this success to other hematologic and solid malignancies is an area of active research and, although challenges remain, novel solutions have led to significant progress over the past decade. Ongoing clinical trials for CAR T cell therapy for T cell malignancies and acute ...